Anti-Human KLRB1 Monoclonal Antibodies and Uses Thereof

The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD161 an inhibit the interaction between CD161 and CLEC2D, and the use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.

Researchers

Kai Wucherpfennig / Byong Ha Kang / Nathan Mathewson / Karl Wittrup

Departments: Department of Chemical Engineering
Technology Areas: Drug Discovery and Research Tools: Antibodies / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living

  • monoclonal antibodies that bind human cd161
    United States of America | Granted | 11,459,389

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies